NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
- Do you, or did you, own shares of Inari Medical, Inc. (NASDAQ: NARI)?
- Did you purchase your shares between February 24, 2022 and February 28, 2024, inclusive?
- Did you lose money in your investment in Inari Medical, Inc.?
- Do you want to discuss your rights?
Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) between February 24, 2022 and February 28, 2024, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Eastern District of New York and alleges violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased or acquired Inari common stock, and/or would like to discuss your legal rights and options please visit Inari Medical, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
According to the Complaint, Defendants repeatedly touted Inari’s financial results and the success of its product sales, but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers.
On February 29, 2024, Inari announced that it received a civil investigative demand by the U.S. Department of Justice (“DOJ”) over certain payments to healthcare professionals relating to meals and consulting services. Inari also warned that “depending on the outcome of the investigation, there may be a material impact on our business, results of operations, or financial condition.” In response to the disclosure, analysts that closely follow the Company immediately reacted negatively and downgraded the stock.
On this news, Inari’s stock price fell $12.14, or nearly 21%, to close at $46.12 per share on February 29, 2024.
If you wish to serve as lead plaintiff, you must move the Court no later than July 12, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
If you purchased or acquired Inari common stock, and/or would like to discuss your legal rights and options please visit Inari Medical, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
ATTORNEY ADVERTISING. © 2024 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Peter Allocco
Investor Relations Manager
Bernstein Liebhard LLP
https://www.bernlieb.com
(212) 951-2030
pallocco@bernlieb.com
